头孢哌酮舒巴坦钠治疗淋病临床评价

Clinical evaluation of cefoperazone sulbactam in the treatment of gonorrhea

目的:探讨对淋病患者采用头孢哌酮舒巴坦钠治疗的临床疗效。方法:选取我院皮肤性病科2010年1月至2015年1月收治的淋病患者104例作为研究对象,回顾性分析其临床资料。按照治疗药物将所有患者划分为对照组和观察组各52例,其中对照组治疗药物为加替沙星联合阿奇霉素,观察组治疗药物为头孢哌酮舒巴坦钠,对比两组临床疗效及不良反应发生率。结果:对照组临床疗效为75.0%,明显低于观察组94.2%,对比差异明显(P<0.05);对照组病原菌转阴率为80.8%,明显低于观察组100.0%,对比差异明显(P<0.05);对照组不良反应发生率为25.0%,明显高于观察组5.8%,对比差异明显(P<0.05);对照组复发率为23.1%,明显高于观察组5.8%,对比差异明显(P<0.05)。结论:头孢哌酮舒巴坦钠治疗淋病临床疗效明显,安全性高,可减少复发,值得推广。

Objectives： To investigate the curative effect of cefoperazone sulbactam sodium for gonorrhea patients. Methods： 104 gonorrhea patients in our hospital between January 2010 and January 2015 were selected as research objects, and their clinical data was retrospectively analyzed. According to drugs received, all patients were divided into control group and observation group, 52 cases in each group. The control group received joint treatment of gatifloxacin and azithromycin, while observation group received cefoperazone sulbactam sodium. The clinical curative effect and the incidence of adverse reactions were compared. Results： The clinical curative effect of control group was 75.0% , significantly lower than the observation group of 94.2% , with significant difference （ P 〈 0. 05 ）. The negative conversion ratio of control group was 80. 8%, significantly lower than the observation group of 100. 0% , with significant difference （ P 〈 0.05 ）. The incidence of adverse reactions in control group was 25.0%, significantly higher than the observation group of 5.8% , with significant difference （ P 〈 0. 05 ）. The recurrence rate in control group was 23.1% , significantly higher than the observation group of 5.8%, with significant difference （ P 〈 0. 05 ）. Conclusion： Cefoperazone sulbactam sodium has remarkable curative effect for gonorrhea, with high safety and low recurrence, which is worth promoting.